The company also announced the initiation of a Phase 2a clinical study for its avenanthramide-based product, following a successful Phase 1 trial. In leadership developments, COSCIENS appointed Anna ...

TORONTO, ONTARIO, April 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company ...

The company also announced the initiation of a Phase 2a clinical study for its avenanthramide-based product, following a successful Phase 1 trial. In leadership developments, COSCIENS appointed ...

In addition, COSCIENS is progressing with the Phase 2a clinical efficacy study for its avenanthramide-based product, following a successful Phase 1 trial. The study is being conducted at the Montreal ...

25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels GlobeNewswire, Inc.

25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels ...

Additionally, COSCIENS has begun a Phase 2a clinical efficacy study for its avenanthramide-based product, following a successful Phase 1 trial. This study, conducted at the Montreal Heart Institute, ...

Ongoing streamlined efficiencies and cost cutting measures taken to refine operations and development pathway forward; Company ended the quarter with US$16.4 million in cash ...